Dr.ย Jianxiangย Wang
MBBS, Master's (Hematology), Chief Physician
Professor & Chief Physician, Hematology
corporate_fareInstitute of Hematology & Blood Diseases Hospital, CAMS, Tianjin
Jianxiang Wang
MBBS, Master's (Hematology), Chief Physician
Prof. Jianxiang Wang is a senior hematologist and physician-scientist at the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin โ one of China's foremost national centres for blood disease research and care. He holds the positions of Professor, Chief Physician, and Director of the National Clinical Research Center for Blood Diseases, which he has led since 2019.
With more than three decades of clinical and academic experience, Prof. Wang has dedicated his career to advancing the understanding and treatment of leukemia and other hematologic malignancies. His medical training began at Shandong Medical College, followed by master's-level research training at Peking Union Medical College and overseas research at Kumamoto University in Japan and the National Institutes of Health in the United States from 1994 to 1999. He progressed to Chief Physician in 1999 and was appointed Professor in 2018. His research spans AML, ALL, CML, CLL, myelodysplastic syndromes, molecular risk stratification, precision leukemia therapy, and CAR-T cell therapy. He is widely recognised as one of China's most prominent leukemia specialists, having contributed to national treatment guidelines and led major multicenter clinical trials in blood cancers.
The Institute of Hematology & Blood Diseases Hospital maintains an International Medical Center for overseas patients. CancerFax can coordinate medical report review and specialist consultation support for international patients, subject to hospital availability and case acceptance.
Why Consider Prof. Jianxiang Wang?
Prof. Wang combines senior clinical expertise in leukemia, national research leadership, guideline-level contributions, and access to advanced blood cancer therapies including CAR-T cell therapy โ making him a highly relevant specialist for complex or relapsed hematologic malignancies.
Areas of Specialisation
Senior expertise in leukemia, MDS, and advanced blood cancer therapies
Prof. Jianxiang Wang's clinical focus covers the full spectrum of acute and chronic leukemias, myelodysplastic syndromes, and hematologic malignancies, with particular strength in precision diagnosis, molecular risk stratification, targeted therapy, and CAR-T cell immunotherapy.
Acute Leukemia
Comprehensive management of acute myeloid and lymphoblastic leukemia, including risk-adapted and molecularly guided treatment.
- arrow_rightMolecular diagnosis and risk stratification in AML
- arrow_rightFLT3-mutated AML and targeted therapy (gilteritinib, midostaurin)
- arrow_rightPrecision combination chemotherapy and novel agent protocols
- arrow_rightRelapsed or refractory AML management
- arrow_rightPhiladelphia chromosome-negative ALL treatment strategies
- arrow_rightPaediatric-inspired regimens for adult ALL
- arrow_rightTargeted and immunotherapy approaches for ALL
Chronic Leukemia & MDS
Management of chronic hematologic malignancies and myelodysplastic syndromes with targeted and risk-adapted approaches.
- arrow_rightCML management with tyrosine kinase inhibitors
- arrow_rightCLL diagnosis, staging, and systemic treatment planning
- arrow_rightMDS risk classification and prognostic assessment
- arrow_rightTreatment selection based on molecular and cytogenetic findings
CAR-T Cell Therapy & Cellular Immunotherapy
Research and clinical application of advanced cellular immunotherapy approaches for hematologic malignancies.
- arrow_rightCD19-directed CAR-T therapy for B-cell malignancies
- arrow_rightCD123รCD33 bicistronic CAR-T research for AML and MDS
- arrow_rightCellular immunotherapy protocols in the context of leukemia research
Procedures & Treatment Approaches
Hematology-focused clinical services and advanced blood cancer treatments
Prof. Wang's clinical practice covers comprehensive leukemia diagnosis, precision treatment planning, targeted and cellular therapies, and expert second opinions for hematologic malignancies.
Leukemia Diagnosis & Molecular Workup
DiagnosisComprehensive molecular and cytogenetic evaluation to guide treatment decisions in leukemia and MDS.
Systemic Leukemia Treatment
Medical OncologyRisk-adapted chemotherapy and combination treatment protocols for acute and chronic leukemias.
Targeted Therapy for Leukemia
Targeted TherapyMolecularly guided targeted agents for AML, CML, and other hematologic malignancies.
Hematopoietic Stem Cell Transplant Planning
TransplantEvaluation and treatment planning in the context of allogeneic and autologous transplant for eligible leukemia patients.
Second Opinion for Blood Cancers
Second OpinionIndependent expert review of leukemia and MDS diagnosis, molecular findings, and treatment plans.
Research & Publications
Leukemia research, CAR-T therapy, and precision oncology contributions
Prof. Wang has an extensive international publication record with over 500 works listed on ORCID and more than 18,000 citations on Google Scholar (h-index above 50). His research spans AML and ALL precision treatment, CAR-T cell therapy, molecular classification, and multicenter clinical trials.
Prof. Wang leads an active national clinical trial programme in leukemia. Eligible patients may have access to investigational therapies and trial enrolment through the National Clinical Research Center for Blood Diseases. CancerFax can provide further information.
Education & Training
Prof. Wang trained in China and completed overseas research fellowships in Japan and at the National Institutes of Health in the United States, building a foundation in both clinical hematology and translational leukemia research.
Clinical Experience
Prof. Wang has spent his entire clinical career at the Institute of Hematology & Blood Diseases Hospital, CAMS, progressing from attending physician to Chief Physician and Professor over more than three decades.
Languages & International
Prof. Wang's consultations are conducted in Mandarin Chinese. The hospital's International Medical Center provides interpreter and coordination support for international patients.
CancerFax can coordinate professional medical interpreter support for international patients communicating in English or other languages.
CancerFax can coordinate professional medical interpreter support for English, Arabic, and other languages when required.
How CancerFax Helps You Access Dr. Jianxiang Wang
CancerFax is a specialist cancer patient-navigation platform. We help international patients prepare structured medical summaries, assess treatment eligibility, and connect directly with Dr. Jianxiang Wang's team โ with full coordination from initial inquiry to consultation.
Medical Report Review
Free review of your pathology results, imaging, molecular profiling, and treatment history โ prepared as a structured clinical summary for Dr. Jianxiang Wang's team.
Treatment Eligibility Screening
CancerFax screens your case for eligibility for treatments and clinical programmes available through Dr. Jianxiang Wang before you travel, so you arrive with a clear pathway.
Case Submission
We coordinate direct case submission to Dr. Jianxiang Wang's department, including all documentation required for clinical review and appointment scheduling.
Appointment & Consultation Coordination
CancerFax manages appointment scheduling with Dr. Jianxiang Wang's team, confirming availability and aligning timelines with your travel plans.
Travel, Visa & Logistics Support
We prepare visa invitation letters, provide hospital-proximity accommodation guidance, and coordinate airport transfers for international patients.
Follow-Up & Continuity of Care
After your consultation or treatment, CancerFax facilitates communication between Dr. Jianxiang Wang's team and your home oncologist for seamless post-treatment follow-up.
Frequently Asked Questions About Prof. Jianxiang Wang
Prof. Jianxiang Wang specialises in leukemia and hematologic malignancies. His verified areas of expertise include acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML), chronic lymphocytic leukemia (CLL), myelodysplastic syndromes (MDS), and relapsed or refractory blood cancers.
Prof. Wang is based at the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College (CAMS & PUMC), in Tianjin, China. This is one of China's leading national centres for hematology research and clinical care.
The Institute of Hematology & Blood Diseases Hospital operates an International Medical Center that supports overseas patients with hematologic disorders. CancerFax can coordinate medical report submission and consultation support for international patients, subject to hospital availability and individual case acceptance.
A second-opinion request can be submitted through CancerFax with the patient's bone marrow biopsy reports, molecular profiling results, pathology, imaging, and treatment history. CancerFax will review the documents, prepare the case for submission, and coordinate the consultation process. The final format and availability depend on the hospital's scheduling.
Yes. Prof. Wang's research programme includes CAR-T cell therapy for hematologic malignancies. His published research includes work on CD123รCD33 bicistronic CAR-T therapy for AML and related blood cancers. The National Clinical Research Center for Blood Diseases, which he directs, runs active trial programmes in this area.
Submit your medical reports using the 'Send Your Reports' button on this page. The CancerFax team will review your case, prepare a structured medical summary, and coordinate the consultation with the hospital team. All logistics, including interpreter coordination if required, are managed by CancerFax.
Connect with Jianxiang Wang Today
Share your medical reports for a free preliminary review. Our patient coordinators will help you understand your options and arrange a direct consultation.
Medical Disclaimer: Information on this page is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making any medical decisions.